3,751 reports of this reaction
1.6% of all INSULIN LISPRO reports
#10 most reported adverse reaction
DRUG DOSE OMISSION is the #10 most commonly reported adverse reaction for INSULIN LISPRO, manufactured by Eli Lilly and Company. There are 3,751 FDA adverse event reports linking INSULIN LISPRO to DRUG DOSE OMISSION. This represents approximately 1.6% of all 239,540 adverse event reports for this drug.
Patients taking INSULIN LISPRO who experience drug dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION is a less commonly reported adverse event for INSULIN LISPRO, but still significant enough to appear in the safety profile.
In addition to drug dose omission, the following adverse reactions have been reported for INSULIN LISPRO:
The following drugs have also been linked to drug dose omission in FDA adverse event reports:
DRUG DOSE OMISSION has been reported as an adverse event in 3,751 FDA reports for INSULIN LISPRO. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION accounts for approximately 1.6% of all adverse event reports for INSULIN LISPRO, making it a notable side effect.
If you experience drug dose omission while taking INSULIN LISPRO, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.